These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20482245)

  • 1. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Med Econ; 2010; 13(2):295-301. PubMed ID: 20482245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of adjunctive therapy with lacosamide for partial-onset epileptic seizures in Belgium.
    Simoens S
    J Med Econ; 2011; 14(3):299-304. PubMed ID: 21488712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orphan drugs and the NHS: should we value rarity?
    McCabe C; Claxton K; Tsuchiya A
    BMJ; 2005 Oct; 331(7523):1016-9. PubMed ID: 16254305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
    Schlander M; Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orphan drugs expenditure in the Netherlands in the period 2006-2012.
    Kanters TA; Steenhoek A; Hakkaart L
    Orphanet J Rare Dis; 2014 Oct; 9():154. PubMed ID: 25304026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of orphan drugs on Latvian budget.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

  • 8. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beware the increasing cost and number of orphan drugs.
    Silverman E
    Manag Care; 2013 Mar; 22(3):10-4. PubMed ID: 23610800
    [No Abstract]   [Full Text] [Related]  

  • 10. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 12. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu.
    Zhang X; Zhou T; Zhou J; Zhang D; Yang Y; Pan J
    BMC Health Serv Res; 2024 Sep; 24(1):1123. PubMed ID: 39334210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
    Arno PS; Bonuck K; Davis M
    Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of European rare disease and orphan drug markets.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Health Policy; 2010 Oct; 97(2-3):173-9. PubMed ID: 20800761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
    Hutchings A; Schey C; Dutton R; Achana F; Antonov K
    Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drugs. Relating price determination to disease prevalence.
    Messori A; Cicchetti A; Patregani L
    BMJ; 2010 Aug; 341():c4615. PubMed ID: 20736283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.